Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 3/20 | 0.54 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | IL1B | P01584 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.53 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23702535 | 1.00 | CRBN (0.66) | CRBNDDB1EGFRCA2HDAC1 | |
| SCHEMBL23702573 | 1.00 | CRBN (0.66) | CRBNDDB1EGFRCA2HDAC1 | |
| SCHEMBL30376233 | 1.00 | CRBN (0.66) | CRBNDDB1EGFRCA2HDAC1 | |
| SCHEMBL23702554 | 0.99 | CRBN (0.67) | CRBNDDB1EGFRCA2HDAC1 | |
| SCHEMBL23751674 | 0.95 | CRBN (0.69) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL26427915 | 0.93 | CRBN (0.66) | CRBNDDB1EGFRCA2HDAC1 | |
| SCHEMBL30502326 | 0.93 | CRBN (0.66) | CRBNDDB1EGFRCA2HDAC1 | |
| SCHEMBL19661945 | 0.93 | CRBN (0.66) | CRBNDDB1EGFRCA2HDAC1 | |
| SCHEMBL26813317 | 0.92 | CRBN (0.64) | CRBNDDB1EGFRCA2HDAC1 | |
| SCHEMBL25189661 | 0.92 | CRBN (0.65) | CRBNDDB1EGFRCA2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent KGaA (DE) | 2025-01-30 | — | — | US | disclosed |
| EP-4426700-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent GmbH (DE) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, UBQLN1, TTI1 | CRBN 2656/4885DDB1 434/4885EGFR 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.